1. Breast cancer: diagnostic and therapeutic options

   • Emilio Bombardieri
   • Luca Gianni

   17 April 2004 Pages: S1 - S2

2. Biomolecular features of clinical relevance in breast cancer

   • Maria Grazia Daidone
   • Angelo Paradiso
   • Manfred Schmitt

   ReviewPaper 17 April 2004 Pages: S3 - S14

   

3. Circulating tumour markers in breast cancer

   • Ettore Seregni
   • Antonio Coli
   • Italian Group RIA-IRMA Test, Italian Association of Nuclear Medicine (AIMN), Italy

   04 May 2004 Pages: S15 - S22

4. Use of tomographic nuclear medicine procedures, SPECT and pinhole SPECT, with cationic lipophilic radiotracers for the evaluation of axillary lymph node status in breast cancer patients

   • Giuseppe Madeddu
   • Angela Spanu

   15 April 2004 Pages: S23 - S34

   

5. Breast scintigraphy today: indications and limitations

   • Orazio Schillaci
   • John R. Buscombe

   ReviewPaper 23 April 2004 Pages: S35 - S45

   

6. Sentinel node detection in pre-operative axillary staging

   • Giuseppe Trifirò
   • Giuseppe Viale
   • Giovanni Paganelli

   22 April 2004 Pages: S46 - S55

   

7. State of the art of current modalities for the diagnosis of breast lesions

   • Cosimo Di Maggio

   ReviewPaper 15 April 2004 Pages: S56 - S69

8. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions

   • K. Scheidhauer
   • C. Walter
   • M. D. Seemann

   ReviewPaper 06 May 2004 Pages: S70 - S79

   

9. Biological characterisation of breast cancer by means of PET

   • Andreas K. Buck
   • Holger Schirrmeister
   • Sven N. Reske

   ReviewPaper 04 May 2004 Pages: S80 - S87

   

10. ^99mTc-MIBI in the evaluation of breast cancer biology

    • Silvana Del Vecchio
    • Marco Salvatore

    23 April 2004 Pages: S88 - S96

    

11. FDG-PET for axillary lymph node staging in primary breast cancer

    • Flavio Crippa
    • Alberto Gerali
    • Emilio Bombardieri

    05 May 2004 Pages: S97 - S102

    

12. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations

    • Nanda C. Krak
    • Otto S. Hoekstra
    • Adriaan A. Lammertsma

    ReviewPaper 22 April 2004 Pages: S103 - S111

    

13. FDG-PET in monitoring therapy of breast cancer

    • H.-J. Biersack
    • H. Bender
    • H. Palmedo

    27 April 2004 Pages: S112 - S117

    

14. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer

    • Wulf Siggelkow
    • Werner Rath
    • Michael Zimny

    14 May 2004 Pages: S118 - S124

    

15. Advantages and limitations of FDG PET in the follow-up of breast cancer

    • Peter Lind
    • Isabel Igerc
    • Klaus Hausegger

    15 April 2004 Pages: S125 - S134

    

16. PET/CT and breast cancer

    • Barbara Zangheri
    • Cristina Messa
    • Ferruccio Fazio

    ReviewPaper 05 May 2004 Pages: S135 - S142

    

17. Current role of bone scan with phosphonates in the follow-up of breast cancer

    • Lorenzo Maffioli
    • Luigia Florimonte
    • Isabel Roca

    16 April 2004 Pages: S143 - S148

18. The curability of breast cancer and the treatment of advanced disease

    • Valentina Guarneri
    • Pier Franco Conte

    ReviewPaper 24 April 2004 Pages: S149 - S161

19. ¹⁸⁶Re-HEDP for metastatic bone pain in breast cancer patients

    • Marnix G. E. H. Lam
    • John M. H. de Klerk
    • Peter P. van Rijk

    29 April 2004 Pages: S162 - S170

    

20. ¹⁵³Sm-EDTMP for bone pain palliation in skeletal metastases

    • Carlo L. Maini
    • Serenella Bergomi
    • Rosa Sciuto

    ReviewPaper 04 May 2004 Pages: S171 - S178

    

21. The choice of the correct imaging modality in breast cancer management

    • Emilio Bombardieri
    • Luca Gianni

    ReviewPaper 04 May 2004 Pages: S179 - S186